Prolylcarboxypeptidase Promotes IGF1R/HER3 Signaling and Is a Potential Target to Improve Endocrine Therapy Response in Estrogen Receptor Positive Breast Cancer

Lei Duan  
Rush University Medical Center

Sarah J Calhoun  
Rush University Medical Center

Ricardo E Perez  
Northeastern University

Virgilia Macias  
University of Illinois at Chicago

Fatima Mir  
Rush University Medical Center

Paolo Gattuso  
Rush University

Carl G. Maki (✉ Carl_Maki@rush.edu)  
Rush University

Research Article

Keywords: PRCP, IGF1R, HER3, endocrine therapy, prognosis

Posted Date: December 10th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1153270/v1

License: ☒ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Prolylcarboxypeptidase (PRCP) is a lysosomal serine protease that cleaves peptide substrates when the penultimate amino acid is proline. Previous studies have linked PRCP to blood-pressure and appetite control through its ability to cleave peptide substrates such as angiotensin II and a-MSH. A potential role for PRCP in cancer has to date not been widely appreciated. Endocrine therapy resistance in breast cancer is an enduring clinical problem mediated in part by aberrant receptor tyrosine kinase (RTK) signaling. We previously found PRCP overexpression promoted tamoxifen (TAM) resistance in estrogen receptor-positive (ER+) breast cancer cells. Currently we tested the potential association between PRCP with breast cancer patient outcome and RTK signaling, and tumor responsiveness to endocrine therapy.

Methods

We analyzed PRCP protein expression by IHC staining of ER+ breast cancer samples and PRCP gene expression in clinical databases and used Kaplan-Meier survival curves to determine the significance of PRCP expression correlation with recurrence free survival and overall survival. We analyzed PRCP-regulated IGF1R/HER3 signaling using immunoblotting in the ER+ MCF7 cell line. We analyzed the therapeutic effect of a PRCP specific inhibitor (PRCPi) and/or endoxifen on tumor growth of ER+ PDX tumors and MCF7 tumors in immunocompromised mice.

Results

We found high PRCP protein levels in tumors associates with worse outcome and earlier recurrence in breast cancer patients, including patients treated with TAM. Analyses of clinical databases showed that PRCP expression correlates with IGF1 and NRG1 expression and their target genes and earlier recurrence in endocrine-treated ER+/HER2- breast cancer patients. Overexpression of PRCP increased IGF1R/HER3 signaling. PRCPi blocked IGF1R/HER3 signaling and enhanced the response of ER+ breast cancer tumors in mice to endoxifen, the active metabolite of TAM.

Conclusions

PRCP is an adverse prognostic marker in breast cancer and a potential target to improve endocrine therapy in ER+ breast cancers.

Introduction

Breast cancer is the most common cancer diagnosed in women and the second leading cause of cancer death. Breast cancer treatment depends in part on the absence or over-expression of estrogen receptor (ER), progesterone receptor (PR), and HER2. Tamoxifen (TAM) is an estrogen receptor antagonist and standard endocrine therapy for premenopausal women with ER(+) breast cancer [1, 2]. For post-menopausal women treatment includes a single aromatase inhibitor (AI) or TAM followed by an AI for
extended periods [3-5]. Despite these approaches, 40-80% of node-positive and 24-30% of node-negative ER+ cases recur with metastasis[6]. Either de novo or acquired resistance contributes to poor prognosis in these patients [7]. To improve outcomes in these patients, it is necessary to identify the factors that promote TAM/antiestrogen therapy resistance and ways to target them.

High expression and activity of IGF-1R and ErbB3 (HER3) are observed in TAM resistant breast cancer cells and contributes to antiestrogen therapy resistance [8-11]. IGF-1R is a receptor tyrosine kinase (RTK), while ErbB3 lacks kinase activity but promotes signaling through dimerization with EGFR-family proteins. The PI3K-AKT and MEK-ERK pathways are activated downstream of IGF-1R and ErbB3 and promote cancer cell proliferation and survival.

PRCP is a serine protease that is mainly localized in the lysosome but may also be extracellular [12]. PRCP cleaves peptide substrates when the penultimate amino acid is proline. PRCP has been linked to blood pressure and appetite control through its cleavage of peptide substrates such as angiotensin II and a-MSH [13-15]. To date, a potential role for PRCP in breast cancer has not been widely appreciated. In our previous study we found PRCP overexpression promotes TAM resistance in ER+ MCF7 breast cancer cells [16]. However, an association between PRCP and breast cancer patient outcome and/or TAM responsiveness in a clinical setting has neither been tested nor established. We found high PRCP expression associates with worse outcome and earlier recurrence in breast cancer patients, including patients treated with TAM and endocrine therapy. Overexpression of PRCP increased IGF1R/HER3 signaling. A small-molecule PRCP inhibitor blocked IGF1R/HER3 signaling in breast cancer cells and enhanced the responsiveness of ER+ breast cancer tumors in mice to endoxifen, the active metabolite of TAM. The results support PRCP as a potential prognostic marker in breast cancer and target to improve endocrine therapy in ER+ breast cancers.

**Methods**

**Cells and Reagents**

MCF7 breast cancer cell line was obtained from ATCC. MCF7 cells were grown in DMEM medium, with 10% fetal bovine serum (FBS), penicillin (100 U/mL) and streptomycin (100 µg/mL). Cells were plated 24h before treatment with different drugs at the indicated concentrations. Recombinant human heregulin (HRG) and IGF1 were obtained from Sigma Chemical Co (St. Louis, MO). PRCP inhibitor (PRCP-7414; catalog number 504044 was from Calbiochem. OSI906 and lapatinib are obtained from Selleckchem.

**Immunoblotting**

Whole cell extracts were prepared by scraping cells in lysis buffer (150 mM NaCl, 5 mM EDTA, 0.5% NP40, 50 mM Tris, pH 7.5), resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (Thermo Fisher Scientific). Antibodies to p-ErbB3 (Y1289), ErbB3, p-IGF1R (Y1135), IGF1R, p-AKT (S473), pan AKT, pmTOR (S2448), mTOR, pS6K (T389), S6K were from Cell Signaling; Phospho-IRS1 (Y612) was from EMD Millpore. IRS1 was from Bethyl
Laboratories. PRCP antibody was from R&D systems. β-actin antibody was from Santa Cruz. Primary antibodies were detected with goat anti-mouse or goat anti-rabbit secondary antibodies conjugated to horseradish peroxidase (Life Technologies), using Clarity chemiluminescence (BIO-RAD). Each presented experiment was a representative of at least two repeatable experiments. (They may ask for all the catalog and lot numbers and dilutions used for the antibodies).

Flow Cytometry

For cell cycle analysis, cells were harvested and fixed in 25% ethanol overnight. The cells were then stained with propidium iodide (25 µg/ml, Calbiochem). Flow cytometry analysis was performed on a Gallios™ Flow Cytometer (Beckman Coulter), analyzed with FlowJo 10 (Treestar Inc). For each sample, 10,000 events were collected. Experiments are done in triplicate and repeated two or three times.

Retroviral and lentiviral infection

Human PRCP cDNA in pFB-retroviral vector was co-transfected with packaging vector (pIK) using Fugene (Promega) into 293FT cells to generate retroviral supernatants. The retroviral supernatants were collected 24h after transfection and then used to infect subconfluent MCF7 cells as described [16].

Tissue Microarray Construction and immunohistochemistry

Primary breast cancer tissues were acquired from archived formalin-fixed, paraffin-embedded (FFPE) pathology tissue blocks in the department of pathology at Rush University Medical Center. For an unbiased analysis, 400 patients consecutively treated from 2000 to 2005 at Rush University Medical Center that have complete follow-up records were selected, including all age and race groups. All the patients are female. For each case, a relevant area of interest was identified on hematoxylin and eosin (H&E) slides and marked along with the corresponding FFPE tissue blocks by two pathology residents in the Department of Pathology. Out of the 400 selected tissue blocks, only 197 cases (127 ER+/Her2 negative cases) contained enough intact tumor tissues for construction of the TMA. The 197 annotated tissues were submitted to the Pathology Tissue Microarray Core Lab at the University of Illinois at Chicago for tissue microarray (TMA) construction. Two representative cylindrical cores of 1.0 mm in diameter were taken from each donor block and re-embedded into recipient paraffin blocks using a TMA Master arrayer (3D Histech Ltd., Budapest, Hungary) following standard procedures [17]. In total, 394 breast cancer tissue cores and 24 de-identified morphologically benign breast tissue cores arranged as orientation markers were distributed onto four TMA blocks. To increase the adherence of the re-embedded tissue, the recipient blocks were incubated overnight at 37°C prior sectioning. Scientific analysis of the cohort of tumors was approved by the Institutional Review Boards at Rush University Medical Center.

The second TMA (TMA-05-7) contains 32 cases of primary ER+ breast cancer tumors from patients treated at Fox Chase Cancer Center that have complete follow-up records. The TMA was obtained from the Fox Chase Biosample Repository Facility under Material Transfer Agreement. The third TMA contains
66 primary tumors of breast cancer patients whose tumors recurred after surgical resection. The TMA was obtained through a collaboration with Dr. Elizabeth Wiley in the Department of Pathology at UIC.

The Proteinatlas validated anti-PRCP antibody (HPA017065) was acquired from SigmaAldrich. All the TMA samples were IHC stained with the PRCP antibodies with hematoxylin counterstain using standard procedures at UIC histology core facility. The IHC staining was interpreted by two pathologists in a blind way and PRCP positivity defined as tumors in which more than 60% of the tumor cells have moderate to strong staining pattern.

**Gene expression omnibus dataset analysis**

GSE25066 dataset contains 290 ER+ breast cancer cases treated with endocrine therapy with recurrence free survival data available [18, 19]. The dataset was analyzed using the Kaplan-Meier Plotter software and database (http://kmplot.com/analysis/). The auto select best cutoff option was used to divide patients into high vs. low expression of genes of interest. Kaplan-Meier survival curves were plotted to compare recurrence free survival times between high vs. low expression of the three genes. Log-rank test was used to determine significance between groups.

**Analysis of gene correlation using the Tumor IMMune Estimation Resource (TIMER)**

The TIMER website (https://cistrome.shinyapps.io/timer/) was used to analyze gene correlation in invasive breast cancer patients from the TCGA database. It contains 1093 cases of invasive breast cancer. Images and statistical analyses are automatically generated by the onsite software.

**In vivo xenografting and therapy**

NOD.Cg-Prkdc<sup>scid</sup>/J (NOD scid) and NOD.Cg-Prkdc<sup>scid</sup>Il2rg<sup>tm1Wjl/Wjl</sup>/Sz (NOD-SCID IL2rγ<sup>−/−</sup>; NSG) mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). The mice were maintained under specific pathogen-free conditions in accordance with the ethical guidelines for the care of these mice at the Comparative Research Center of Rush University Medical Center. The mice were 6-8 weeks of age at the time of transplant. All mice were subcutaneously inoculated with estrogen pellets (1.5mg/pellet, 90-day release) obtained from Innovative Research of America before xenografting.

For MCF7 cell transplantation, 10 million of disaggregated MCF7 cells (passage three from ATCC) were resuspended in 100 ml of a 1:1 v/v mixture of cold DMEM:Matrigel (BD Biosciences, San Jose, CA) and kept on ice until transplantation. Cells were subcutaneously injected into the left mammary fat pads of NOD scid mice using 23G needles. When tumors reached the size of 300 mm<sup>3</sup>, the mice were randomly divided into 4 groups (5 mice/group) for treatment.

The ER+/PR+/ErbB2- PDX tumor (TM00386) was obtained from Jackson Laboratory. When the PDX tumor reached 1 cm<sup>3</sup> volume, the tumor bearing mice were euthanized. Using aseptic technique, the tumor was removed and then minced into the smallest possible pieces using forceps and a scalpel. The minced tumors were transferred into a 1 ml syringe and then subcutaneously injected into 20 NSG mice.
(100 µl/mice) using a 14G needle. When tumors reached 300 mm³, the mice were randomly divided into four groups (5 mice/group) for treatment.

For both MCF7 tumors and PDX tumors, the mice were treated with vehicle, endoxifen (20 mg/kg/day, 5 days/week), PRCPi (20mg/kg/day, 5 days/week), or combination of endoxifen and PRCPi. Both endoxifen and PRCP were solubilized in Cremophor EL formulation for intraperitoneal injection. Tumor growth and body weight were then monitored with a caliper twice per week. When tumors reached 1 cm³ volume, the mice were euthanized. At necropsy, the tumors were harvested for further analysis.

Statistical analysis

One-way analysis of variance (ANOVA) and Student's t-test were used to determine the statistical significance of differences among experimental groups. Student's t-test was used to determine the statistical significance between control and experimental groups.

Results

High expression of PRCP protein in breast cancers and associated with worse outcome

The current study was undertaken to examine a potential role for PRCP in breast cancer patient outcome and endocrine therapy resistance. To this end, we first created a tissue microarray (TMA) from estrogen receptor positive (ER+) breast cancer patients treated at our institute from 2000-2005 and for whom long-term survival data is available. Representative staining patterns are shown in Fig 1A. The criteria for PRCP positivity was that more than 60% of cells have moderate to strong PRCP staining. The results showed PRCP positivity associates with significantly reduced overall survival in these patients (Fig 1B). We carried out a similar analysis using a 32 breast patient TMA from Fox Chase Cancer Center (Fig 1C). The data also showed high PRCP expression associates with reduced overall survival. Next, we analyzed the association between PRCP positivity and tumor recurrence in a 66 patient TMA from recurrent breast cancer patients. The results showed PRCP positivity correlates with reduced RFS (earlier recurrence) in all patients, including patients treated with TAM (Fig 1D). Overall, the results in Fig 1 indicate high expression of PRCP is associated with worse outcome and earlier recurrence in breast cancer patients, including in patients treated with endocrine therapy.

Overexpression of PRCP increases AKT-mTORC1 and IGF1R/HER3 signaling

Aberrant RTK signaling contributes to endocrine therapy resistance in breast cancer. AKT and mTORC1 are activated downstream of RTKs and promote endocrine therapy resistance [20-22]. We reported PRCP maintains levels of activated AKT (S473 phosphorylated) in pancreatic cancer cells [23]. Therefore, we hypothesized PRCP may promote endocrine therapy resistance by regulating RTK signaling, including activation of AKT. To examine this, we first tested the effect of PRCP knockdown in ER+ MCF7 breast cancer cells using two different shRNAs. The results showed PRCP knockdown reduced levels of activated (S473 phosphorylated) AKT in MCF7 cells (Fig 2A). We also tested the effect of PRCP
overexpression. B6-9 cells are TAM-resistant MCF7 cell derivatives that stably over-express PRCP (Fig. 2B). As shown in Fig 2C, B69 cells expressed higher basal levels of activated (S473 phosphorylated) AKT compared to MCF7 cells and maintained activated AKT levels after TAM treatment, whereas in MCF7 cells activated AKT was lost in response to TAM. mTORC1 was also more activated in PRCP overexpressing B69 cells compared to MCF7 cells, evidenced by increased mTOR phosphorylation at S2448 (autophosphorylation site) and increased S6K phosphorylation at T389 (mTORC1 substrate).

Lastly, we examined the effect of PRCP overexpression or inhibition on signaling downstream of individual RTKs. Overexpression or activation of RTKs such as EGFR, HER2 and IGF1R can cause resistance to tamoxifen through activation of PI3K/AKT and MAPK pathways in breast cancer (BC) cell lines [20-22] and are associated with poor outcome in tamoxifen-treated patients [24, 25]. As MCF7 cells express very low levels of EGFR/HER2 but high levels of HER3 (data not shown), we used heregulin (HRG) to activate HER3 in MCF7 and B6-9 cells. We found B6-9 cells had higher Y1289 phosphorylation (activation) of ErbB3 in response to the ErbB3 ligand HRG than MCF7 cells (Fig 2D). B6-9 cells also showed higher phosphorylation (activation) of IRS1 (Y612) and AKT (S473) than MCF7 cells in response to both HRG and insulin (INS) (Figs 2D and E). Importantly, co-treatment of B6-9 cells with a PRCP inhibitor PRCP-7414 (PRCPi) blocked or reduced ErbB3, IRS1, and AKT activation in response to HRG or INS (Fig 2D and E). We previously reported that B6-9 cells are less sensitive to 4OHTAM compared with MCF7 cells [16]. We tested if PRCPi can sensitize MCF7 and B6-9 cells to endoxifen, an active metabolite of TAM. The cells were treated with endoxifen and/or PRCPi for 72 hrs and the percentage of cells with sub-G1 DNA content used as an indicator of cell death. As shown in Fig. 2F, B6-9 cells were less susceptible to endoxifen-induced death compared with MCF7 cells. PRCPi alone (5 mM) induced a slight increase in death in both MCF7 and B6-9 cells. However, combination of PRCPi with endoxifen induced a significant increase in cell death. The results support that PRCP promotes endocrine therapy (TAM, endoxifen) resistance and this is associated with heightened IGF1R/HER3 signaling.

**PRCP gene expression correlates with IGF1 and NRG1 expression and earlier recurrence of endocrine therapy treated breast cancer patients.**

The above results suggest PRCP promotes IGF1R/HER3 signaling in ER+ breast cancer cells. We sought to investigate if PRCP promotes IGF1R/HER3 signaling in clinical patients. First, we analyzed correlation between PRCP gene expression and IGF1 (IGF1R ligand) and NRG1 (HER3 ligand) expression (Fig. 3A) in 1093 cases of invasive breast cancer (TCGA database) using the TIMER software. The results showed that PRCP positively correlated with IGF1 and NRG1 (Fig 3A, p values indicate significance). EGR1, KLF2, and CTGF are target genes activated downstream of IGF1 [26]. ETV1 is a target gene activated downstream of NRG1 signaling [27]. We found that IGF1 positively correlates with EGR1, KLF2, and CTGF and NRG1 positively correlates with ETV1 with high significance (Fig. 3B). PRCP also positively correlated with EGR1, KLF2, CTGF, and ETV1 (Fig. 3C. p values indicate significance). These results suggest that high expression of PRCP coincides with heightened IGF1/HER3 signaling in clinical patients. Next, we analyzed the GSE25066 dataset that contains 290 ER+/HER2- breast cancer patients treated with endocrine therapy [18, 19]. Kaplan-Meier survival curve analysis showed that high expression of PRCP, IGF1 and NRG1 significantly correlates with decreased RFS in the endocrine therapy treated
patients (Fig. 4A). High expression of EGR1 and ETV1 also significantly correlates with decreased RFS in these patients (Fig. 4B). Altogether, these results indicate that high expression of PRCP correlates with increased IGF1R/HER3 signaling and endocrine therapy resistance in clinical patients.

**PRCP inhibitor combined with endoxifen causes regression of ER+ breast cancer tumors in mice**

Next, we wished to ask if PRCP inhibition is effective against ER+ breast cells and tumors when given alone, or in combination with endocrine therapy. TRC cells are TAM-resistant derivatives of MCF7 cells that were generated by prolonged exposure to TAM [16]. First, we treated MCF7 and TRC cells with increasing doses of endoxifen alone or in combination with PRCP inhibitor (5 mM). We monitored proliferation by MTT assay and cell death by the percentage of cells with sub-G1 DNA content. Combination of PRCPi plus endoxifen caused a pronounced inhibition of proliferation by MTT assay in both MCF7 and TRC cells (Fig. 5A) and a pronounced increase in cell death by sub-G1 cells in TRC cells (Fig. 5B). The results indicate PRCP inhibitor can increase endoxifen sensitivity in ER+ and TAM resistant cells. Next, we tested if inhibition of IGF1R and HER3 sensitizes MCF7 and TRC cells to endoxifen. OSI906 is an IGF1R inhibitor. HER3 does not have an active kinase domain so we used lapatinib that inhibits EGFR and HER2 that are HER3 dimerization partners. It is noteworthy that lapatinib blocks HRG-induced phosphorylation of HER3 in MCF7 cells (data not shown). OSI906 alone modestly sensitized MCF7 cells but not TRC cells to endoxifen while lapatinib alone did not sensitize MCF7 and TRC cells to endoxifen (Fig. 5C). However, combined treatment with OSI906 and lapatinib significantly sensitized both MCF7 and TRC cells to to endoxifen (Fig. 5C). Lastly, we established ER+ MCF7 cell tumors and an ER+ human breast PDX tumor in the mammary fat pads of NSG mice. Tumor bearing mice were then treated with vehicle, PRCPi alone, endoxifen alone, or both, and tumor growth monitored over 5 weeks. As shown in Figs 5D and E, both endoxifen alone and PRCPi alone blocked or slowed the growth of MCF7 and PDX tumors. Strikingly, however, combined treatment with PRCPi and endoxifen caused a significant regression of the MCF7 and PDX tumors. Notably, mice appeared to tolerate the drug combination treatment without obvious weight loss (Figure S1). Immunoblots of tumor lysates showed pAKT (S473) was reduced by PRCPi compared with vehicle or endoxifen treated tumors (Fig. 5F and G). These results suggest PRCPi is effective in vivo in suppressing tumor growth as a single drug and can synergistically induce regression of ER+ tumors when combined with endoxifen.

**Discussion**

PRCP is a serine protease that localizes mainly in the lysosome but can also be extracellular [12]. The vast majority of previous studies have linked PRCP to blood pressure and appetite control through its cleavage of peptide substrates angiotensin II and a-MSH [13-15]. A role for PRCP in breast cancer or other cancers has, to date, not been widely recognized. In the current report we found high PRCP protein expression associates with worse outcome and earlier recurrence in breast cancer patients, including ER+ patients treated with TAM. In addition, we found that high expression of PRCP correlates with increased expression of IGF1/NRG1 and their target genes and earlier recurrence of endocrine treated ER+ breast cancer patients. Overexpression of PRCP increased IGF1R/HER3 signaling and AKT-mTORC1 activation
in ER+ breast cancer cells. A small-molecule PRCP inhibitor blocked IGF1R/HER3 signaling in breast cancer cells, and enhanced the responsiveness of human ER+ breast cancer tumors in mice to endoxifen, an active metabolite of TAM. Taken together, the results support PRCP as a potential prognostic marker for outcome in breast cancer patients and a novel target to improve endocrine therapy in ER+ breast cancers.

We found high PRCP expression is associated with reduced overall survival in ER+ breast cancer patients and earlier recurrence in ER+ breast cancer patients treated with endocrine therapy. This suggests high PRCP expression may be a marker for poor outcome and poor response to endocrine therapy in these patients. Indeed, cells with overexpression of PRCP show resistance to TAM or endoxifen and are sensitized to these treatments by PRCP inhibitor. This suggests the association between high PRCP expression and poor outcome in breast cancer is not limited to ER+ patients.

A question that arises is how PRCP promotes endocrine therapy resistance. The AKT-mTORC1 pathway is activated downstream of multiple RTKs and contributes to endocrine therapy resistance. Cells with overexpression of PRCP had heightened AKT-mTORC1 compared to parental MCF7 cells both basally and in response to TAM. High expression and activity of IGF-1R and EGFR/HER2 promote TAM resistance and are associated with worse patient outcome in breast cancer [20-22] [24, 25]. B6-9 cells with overexpression of PRCP displayed increased IGF-1R and ErbB3 signaling and heightened AKT activation in response to heregulin (ErbB3 ligand) and insulin (IGF1R/IR ligand) compared to MCF7. Combined inhibition of IGF1R and HER3 sensitizes TRC cells to endoxifen. Moreover, analyses of clinical databases showed that PRCP expression correlates with IGF1/NRG1 expression and their target genes EGR1, KLF2, CTGF, and ETV1. High expression of PRCP, IGF1, NRG1, EGR1, KLF2, and ETV1 also significantly correlates with reduced RFS of endocrine treated patients. Overall, the results support a model in which PRCP promotes endocrine therapy resistance by promoting IGF1R/HER3 signaling and subsequent activation of AKT. A remaining but unanswered question is how PRCP increases or promotes IGF1R/HER3 signaling. PRCP cleaves different GPCR agonist peptides such as angiotensin II and a-MSH, though the full repertoire of PRCP substrates is not established. There is abundant crosstalk between GPCR and RTK signaling pathways that regulate cancer cell proliferation. Though it remains unknown, we hypothesize PRCP substrate cleavage regulates or alters the cross-talk between GPCRs and RTKs, and in this way increases RTK signaling and subsequent endocrine therapy resistance.

The PRCP inhibitor PRCP-7414 (PRCPi) when given alone reduced growth of ER+ MCF7 cell line and PDX tumors in mice. As expected, this was associated with a reduced levels of phosphorylated (activated) AKT in tumor lysates. The results indicate PRCPi is bioavailable with anti-tumor activity and reduces activated AKT in tumors as it does in cells. TAM is metabolically activated to 4-OHT and endoxifen. Endoxifen alone also reduced growth of ER+ MCF7 cell line tumors and growth of ER+ PDX tumors in mice. Most importantly, combined PRCPi plus endoxifen caused the most pronounced reduction in tumor growth. These results support PRCP as a potential viable target to increase endocrine therapy responses in ER+ tumors, though side effects including blood pressure changes may occur. Future directions may include developing effective ways to inhibit PRCP while minimizing side effects.
Conclusions

PRCP is an adverse prognostic marker and a potential therapeutic target to enhance endocrine therapy response in ER+ breast cancer patients.

Declarations

Ethics approval and consent to participate

The IHC staining analysis of the cohort of tumors was approved by the Institutional Review Boards at Rush University Medical Center.

The in mice xenotransplated tumor studies was approved by the Institutional animal care and use committee at Rush University Medical Center.

Consent for publication

All authors are consent for publication of the manuscript.

Availability of data and materials

The invasive breast cancer dataset for analysis of gene correlation is available at The TIMER website (https://cistrome.shinyapps.io/timer/).

The GSE25066 dataset was available at the Kaplan-Meier Plotter website (http://kmplot.com/analysis/).

Competing interests

All authors declare no conflict of interests.

Funding

This work was supported in part by a grant from the National Cancer Institute (R01CA200232-05) and by a DoD breast cancer grant (Grant 11895064) to C.G.M.

Author contributions

Experimental design, L. D. and C.G.M. Experimental work and interpretation, L.D., S.C., R.E.P., and V.M. IHC interpretation, F.M. and P.G. Writing, L. D. and C.G.M.

References

1. Puhalla S, Brufsky A, Davidson N: Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast (Edinburgh, Scotland) 2009, 18 Suppl 3:S122-130.
2. Burstein HJ, Griggs JJ: **Adjuvant hormonal therapy for early-stage breast cancer.** *Surgical oncology clinics of North America, 19*(3):639-647.

3. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T: **Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.** *Lancet 2002, 359*(9324):2131-2139.

4. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M et al: **A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.** *The New England journal of medicine 2005, 353*(26):2747-2757.

5. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I et al: **Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.** *Lancet 2007, 369*(9561):559-570.

6. Kabos P, Borges VF: **Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.** *Expert opinion on pharmacotherapy, 11*(5):807-816.

7. Musgrove EA, Sutherland RL: **Biological determinants of endocrine resistance in breast cancer.** *Nat Rev Cancer 2009, 9*(9):631-643.

8. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, 2nd, de Cremoux P, Stenvang J et al: **Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.** *Breast cancer research and treatment 2009, 114*(2):263-275.

9. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD: **Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.** *International journal of cancer 2007, 120*(9):1874-1882.

10. Zhang Y, Wester L, He J, Geiger T, Moerkens M, Siddappa R, Helmijr JA, Timmermans MM, Look MP, van Deurzen CHM et al: **IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.** *Oncogene 2018, 37*(14):1869-1884.

11. Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J, van de Water B: **Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.** *Breast cancer research : BCR 2011, 13*(3):R52.

12. Skidgel RA, Erdos EG: **Cellular carboxypeptidases.** *Immunological reviews 1998, 161*:129-141.
13. Luft FC: The renin-angiotensin system and prolylcarboxypeptidase. Journal of molecular medicine (Berlin, Germany), 95(5):461-463.

14. Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E, Liu ZW, Gao XB, Diament A, Haus KA, Shariat-Madar Z et al: Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. The Journal of clinical investigation 2009, 119(8):2291-2303.

15. Wang J, Matafonov A, Madkhali H, Mahdi F, Watson D, Schmaier AH, Gailani D, Shariat-Madar Z: Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor). Current molecular medicine, 14(9):1173-1185.

16. Duan L, Motchoulski N, Danzer B, Davidovich I, Shariat-Madar Z, Levenson VV: Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. The Journal of biological chemistry 2011, 286(4):2864-2876.

17. Fedor HL, De Marzo AM: Practical methods for tissue microarray construction. Methods in molecular medicine 2005, 103:89-101.

18. Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Ohtani S et al: Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Breast cancer research and treatment 2014, 143(2):403-409.

19. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H et al: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. Jama 2011, 305(18):1873-1881.

20. Miller TW, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP et al: Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer research 2009, 69(10):4192-4201.

21. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clinical cancer research : an official journal of the American Association for Cancer Research 2004, 10(23):8059-8067.

22. DeGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, Peralba JM, Hidalgo M: Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Annals of oncology : official journal of the European Society for Medical Oncology 2003, 14(7):1051-1056.
23. Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG: The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. *The Journal of biological chemistry* 2014, **289**(31):21694-21705.

24. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2004, **10**(17):5670-5676.

25. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlonemagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G et al: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2005, **11**(13):4741-4748.

26. Pais RS, Moreno-Barriuso N, Hernandez-Porras I, Lopez IP, De Las Rivas J, Pichel JG: Transcriptome analysis in prenatal IGF1-deficient mice identifies molecular pathways and target genes involved in distal lung differentiation. *PloS one* 2013, **8**(12):e83028.

27. Shekhar A, Lin X, Liu FY, Zhang J, Mo H, Bastarache L, Denny JC, Cox NJ, Delmar M, Roden DM et al: Transcription factor ETV1 is essential for rapid conduction in the heart. *The Journal of clinical investigation* 2016, **126**(12):4444-4459.

**Figures**
Figure 1

PRCP-positive BC patients have poor outcomes. A. Slides containing cores of breast cancer tissues were deparaffinized and stained with primary PRCP antibody (# HPA017065, Human Protein Atlas). PRCP displayed a granular cytoplasmic pattern. TMA staining was scored based on intensity (negative, weak, moderate, and strong) and percent cell staining. The criteria for PRCP positivity are that more than 60% of the cells have moderate to strong staining. B. Primary breast cancer tissues from 127 ER+ BC patients treated at Rush Medical Center from 2000-2005 were stained for PRCP. Kaplan-Meier curves show overall survival (OS) is significantly lower (p=0.000) in PRCP positive (n=57) patients compared with PRCP negative patients (n=70). C. Primary breast cancer tissues of 32 ER+ BC patients (Fox Chase TMA) were stained for PRCP. Kaplan-Meier shows OS is significantly shorter (p=0.016) in PRCP positive patients (n=14) compared with PRCP negative patients (n=18). D. Left panel: primary breast cancer tissues of 66 recurrent BC patients treated at UIC from 1994-2004 were stained for PRCP. Kaplan-Meier shows RFS is
significantly shorter ($p=0.010$) in PRCP positive patients ($n=48$) compared with PRCP negative patients ($n=18$). Right panel: among the 66 patients, 24 ER+ patients were treated with tamoxifen. Kaplan-Meier shows RFS is significantly shorter ($p=0.026$) in PRCP positive patients ($n=7$) compared with PRCP negative patients ($n=17$).

**Figure 2**
PRCP promotes ErbB3/IGFR/IRS1/AKT activation. A. Lysates of MCF7 cells infected with control shRNA of PRCP shRNA (#1 and #2) were immunoblotted for the indicated proteins. B. Lysates of MCF7 and B6-9 cells were immunoblotted for the indicated proteins. C. MCF7 and B-9 cells were treated with 4OHTAM (10μM) for 24 hrs. Lysates were immunoblotted for the indicated proteins. Serum starved MCF7 and B6-9 cells were pretreated with PRCPi (10μM) and then treated with heregulin (HRG) (D) or insulin (INS) (E) for 10 min. Lysates were immunoblotted for the indicated proteins. F. The cells were treated with Endoxifen (END, 5 μM and 10 μM) and/or PRCPi (5 μM) for 72 hrs and then analyzed with FACS for cell cycle. Average (triplicate) % sub-G1 cells were presented with SD indicated.

Figure 3
PRCP gene correlates with IGF1/NRG1 genes and their target genes in invasive breast cancer. TIMER analysis of gene correlation in 1093 cases of invasive breast cancer showed that PRCP positively correlates with IGF1 and NRG1 (A). IGF1 positively correlates with EGR1, KLF2, and CTGF and NRG1 positively correlates with ETV1 (B). PRCP positively correlates with EGR1, KLF2, CTGF, and ETV1 (C). Correlation coefficient and p values are indicated on the graphs.

Figure 4

High expression of PRCP, IGF1/NRG1 and target genes correlates with poor prognosis. A. Analysis of PRCP, IGF1, and NRG1 gene expression in the GSE25066 dataset for ER+/HER2- BC patients treated with endocrine therapy. Kaplan-Meier shows that RFS is significantly shorter in PRCP high, IGF1 high, and NRG1 high patients compared with gene expression low patients. B. The IGF1 target genes EGR1 (AT225) and the NRG1 target gene ETV1 also significantly correlates with reduced RFS in the patients. P values (log-rank test) and case numbers are indicated on the graphs.
PRCPi sensitizes cells and tumors to endoxifen. MCF7 and TRC cells were treated with endoxifen and/or PRCPi for three days. Cells were analyzed with MTT assay or FACS for sub-G1. Average (8 replicates) relative MTT absorbance (A) and Average (triplicate) % sub-G1 cells (B) are presented with SD indicated. There are significant differences between PRCPi and PRCPi plus 5 µM and 10 µM endoxifen (p<0.05) in MCF7 and TRC cells in A. There are significant differences between PRCPi and PRCPi plus 5 µM and 10
µM endoxifen in TRC cells in B. C. MCF7 and TRC cells were treated with endoxifen and/or OSI906 (5 µM) or lapatinib (2 µM) for three days. Cells were analyzed with FACS for sub-G1. Average (triplicate) % sub-G1 cells are presented with SD indicated. There are significant differences (p<0.05) between NT and endoxifen, endoxifen and endoxifen plus OSI906, OSI906 and OSI906 plus endoxifen, NT and OSI906 plus lapatinib, OSI906 plus lapatinib and endoxifen plus OSI906 plus lapatinib in MCF7 cells. There are no significant differences (p>0.05) between NT and endoxifen, endoxifen and endoxifen plus OSI906, OSI906 and OSI906 plus endoxifen, endoxifen and endoxifen plus lapatinib in TRC cells. There are significant differences (p<0.01) between NT and OSI906 plus lapatinib, between OSI906 plus lapatinib and OSI906 plus lapatinib plus endoxifen. D and E. MCF7 tumors and ER+ PDX tumors were treated with vehicle. Endoxifen, PRCPi, or combination for the indicated times. Log-tumor volumes were plotted with SE indicated. There are significant differences between vehicle and endoxifen or PRCPi (p<0.05) in both tumors. There are significant differences between single drug and combination therapies (p<0.05) in both tumors. F and G. At necropsy, tumors were harvested. Lysates were immunoblotted for the indicated proteins.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryDataPRCPendocrinetherapy.pdf](#)